These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 8426742)

  • 1. Raf revertant cells resist transformation by non-nuclear oncogenes and are deficient in the induction of early response genes by TPA and serum.
    Kolch W; Heidecker G; Troppmair J; Yanagihara K; Bassin RH; Rapp UR
    Oncogene; 1993 Feb; 8(2):361-70. PubMed ID: 8426742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant.
    Rapp UR; Troppmair J; Beck T; Birrer MJ
    Oncogene; 1994 Dec; 9(12):3493-8. PubMed ID: 7970709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. v-erbA cooperates with bFGF in neuroretina cell transformation.
    Garrido C; Li RP; Samarut J; Gospodarowicz D; Saule S
    Virology; 1993 Feb; 192(2):578-86. PubMed ID: 7678474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of the p72-74 RAF-1 kinase in 3T3 fibroblasts expressing ras or src oncogenes.
    Reed JC; Yum S; Cuddy MP; Turner BC; Rapp UR
    Cell Growth Differ; 1991 May; 2(5):235-43. PubMed ID: 1888699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imbalanced expression of cellular nuclear oncogenes caused by v-sis/PDGF-2.
    Sonobe MH; Bravo R; Armelin MS
    Oncogene; 1991 Sep; 6(9):1531-7. PubMed ID: 1923519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple pathways for activation of MAP kinases.
    Mitra G; Weber M; Stacey D
    Cell Mol Biol Res; 1993; 39(5):517-23. PubMed ID: 8173594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
    Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
    Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transformation-resistant mos revertant is unable to activate MAP kinase kinase in response to v-mos or v-raf.
    Topol LZ; Marx M; Calothy G; Blair DG
    Cell Growth Differ; 1995 Jan; 6(1):27-38. PubMed ID: 7718484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. v-myc and v-raf act synergistically to induce B-cell tumors in pristane-primed adult BALBC mice.
    Kurie JM; Morse HC; Principato MA; Wax JS; Troppmair J; Rapp UR; Potter M; Mushinski JF
    Oncogene; 1990 Apr; 5(4):577-82. PubMed ID: 2183159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Aminopurine abolishes EGF- and TPA-stimulated pp33 phosphorylation and c-fos induction without affecting the activation of protein kinase C.
    Mahadevan LC; Wills AJ; Hirst EA; Rathjen PD; Heath JK
    Oncogene; 1990 Mar; 5(3):327-35. PubMed ID: 2107492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transactivation of c-fos and beta-actin genes by raf as a step in early response to transmembrane signals.
    Jamal S; Ziff E
    Nature; 1990 Mar; 344(6265):463-6. PubMed ID: 2157161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence that activation of the Egr-1 promoter by v-Raf involves serum response elements.
    Rim M; Qureshi SA; Gius D; Nho J; Sukhatme VP; Foster DA
    Oncogene; 1992 Oct; 7(10):2065-8. PubMed ID: 1408148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells.
    Kolch W; Heidecker G; Lloyd P; Rapp UR
    Nature; 1991 Jan; 349(6308):426-8. PubMed ID: 1992343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of a new class of 'flat' revertants from ras-transformed NIH3T3 cells using cis-4-hydroxy-L-proline.
    Yanagihara K; Ciardiello F; Talbot N; McGeady ML; Cooper H; Benade L; Salomon DS; Bassin RH
    Oncogene; 1990 Aug; 5(8):1179-86. PubMed ID: 2202950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
    Lehtola L; Sistonen L; Koskinen P; Lehväslaiho H; Di Renzo MF; Comoglio PM; Alitalo K
    J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AP-1 (Fos-Jun) regulation by IP-1: effect of signal transduction pathways and cell growth.
    Auwerx J; Sassone-Corsi P
    Oncogene; 1992 Nov; 7(11):2271-80. PubMed ID: 1437149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A role for Ras in v-Crk transformation.
    Greulich H; Hanafusa H
    Cell Growth Differ; 1996 Nov; 7(11):1443-51. PubMed ID: 8930393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated expression of the junB proto-oncogene is essential for v-fos induced transformation of Rat-1 cells.
    Van Amsterdam JR; Wang Y; Sullivan RC; Zarbl H
    Oncogene; 1994 Oct; 9(10):2969-76. PubMed ID: 8084600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ornithine decarboxylase induction in transformation by H-Ras and RhoA.
    Shantz LM; Pegg AE
    Cancer Res; 1998 Jul; 58(13):2748-53. PubMed ID: 9661886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.